Skip to main content


Figure 3 | Molecular Cancer

Figure 3

From: High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde

Figure 3

Down-regulation of c-FLIP L/S and Mcl-1 in TRAIL-treated metastatic cancer cells. PC3 and PC3-MM2 cells were treated with 2 or 10 ng/ml TRAIL for 6 h, and KM12 and KM12L4A cells were treated with 5 or 25 ng/ml TRAIL for 8 h. After TRAIL treatment, the mRNA expression level of c-FLIPL/S (FLIPL/S) was measured by quantitative real-time RT-PCR (A), and protein levels of FLIPL/S and Mcl-1 were measured by Western blot analysis (B), respectively. β-Actin (Actin) was used as a loading control.

Back to article page